CagrilintidevsLiraglutide

Cagrilintide is a long-acting analogue of amylin, a 37-amino-acid peptide hormone naturally co-secreted with insulin from pancreatic beta cells after meals. Native amylin plays a crucial but often overlooked role in metabolic regulation — it signals satiety, slows gastric emptying, and suppresses post-meal glucagon secretion through mechanisms entirely distinct from the GLP-1 pathway.

Cagrilintide activates amylin receptors, which are heterodimeric complexes formed by the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These receptors are concentrated in the area postrema and the nucleus tractus solitarius in the brainstem — regions outside the blood-brain barrier that can directly sense circulating peptides. Activation of these neurons triggers ascending satiety signals to the hypothalamus, reducing meal size and food-seeking behavior through pathways that are neuroanatomically separate from GLP-1 signaling.

This distinct mechanism is why cagrilintide produces additive appetite suppression when combined with semaglutide (as CagriSema) — the two peptides target different populations of neurons within the brain's appetite control circuitry. Cagrilintide has been engineered with acylation modifications that enable albumin binding, extending its half-life from minutes (native amylin) to approximately one week, making it suitable for weekly subcutaneous dosing.

Liraglutide is a GLP-1 receptor agonist with 97% amino acid homology to native human GLP-1(7-37), modified by a single amino acid substitution (Lys34Arg) and attachment of a C16 palmitoyl fatty acid chain to Lys26 via a glutamic acid spacer. This acylation is the key pharmacological modification — the C16 fatty acid chain non-covalently binds to serum albumin after injection, creating an albumin-bound depot that is slowly released, extending the half-life from 1-2 minutes (native GLP-1) to approximately 13 hours. The acylation also confers resistance to DPP-4 enzymatic degradation.

Liraglutide activates the GLP-1 receptor (GLP-1R), a Gs-coupled GPCR expressed in pancreatic beta cells, the hypothalamus, the gastrointestinal tract, and the cardiovascular system. In pancreatic beta cells, GLP-1R activation increases intracellular cAMP, which enhances glucose-stimulated insulin secretion (GSIS) through PKA and Epac2 (exchange protein activated by cAMP) signaling. Crucially, this insulin secretion is glucose-dependent — it only occurs when blood glucose is elevated, which greatly reduces the risk of hypoglycemia compared to insulin or sulfonylureas. GLP-1R activation also suppresses glucagon secretion from alpha cells (reducing hepatic glucose output), promotes beta cell proliferation, and inhibits beta cell apoptosis.

The weight loss mechanism operates primarily through hypothalamic GLP-1R activation. GLP-1 receptors in the arcuate nucleus and paraventricular nucleus reduce appetite by activating POMC/CART (anorexigenic) neurons and inhibiting NPY/AgRP (orexigenic) neurons. This produces a sustained reduction in hunger and food intake. In the GI tract, GLP-1R activation delays gastric emptying, prolonging postprandial satiety and slowing the rate of nutrient absorption. The combined effects on appetite reduction and gastric emptying produce clinically meaningful weight loss — approximately 5-8% of body weight in clinical trials at the 3.0 mg daily dose (Saxenda). The LEADER cardiovascular outcomes trial demonstrated that liraglutide also reduces major adverse cardiovascular events, likely through anti-inflammatory, anti-atherogenic, and cardioprotective effects of GLP-1R activation in vascular endothelium and cardiomyocytes.